Prostate Cancer: Progress and Promise, Part V
Thursday, January 30, 2014 from 7:00 PM to 10:00 PM (PST)
San Francisco, CA
Plan to attend this CME Ancillary Meeting at the
2014 Genitourinary Cancers Symposium
Not an official event of the 2014 GU Cancers Symposium. Not sponsored or endorsed by any of the cosponsoring organizations of the 2014 GU Cancers Symposium.
Thursday, January 30, 2014
San Francisco Marriott Marquis
The Club Room, Second Level
Registration desk opens at 7:15pm
Light refreshments and snacks will be available.
CME Activity begins at 7:30pm and ends at 9:45pm
Over the last three years we have seen major improvement in prognosis for prostate cancer patients. Trials showing improved survival for men with previously untreatable disease have been conducted in improved hormone therapy, chemotherapy, a new form of injectable radiotherapy, and a form of vaccination. While these are exciting developments, oncologists are still just beginning to introduce these therapies in clinical practice. One of the real challenges is how we will try to ensure the patients get optimal exposure to all of these drugs; for example, what order do we use them in? Do we use them in combination, and which do we give first? We are only just beginning to now tease those details apart in prostate cancer. This symposium will seek to answer your challenging questions and provide the most up to date information for clinical practice and give insight into novel therapies for the future.
Symposium Chairman: Howard I. Scher, MD
Chief, Genitourinary Oncology Service and D. Wayne Calloway Chair in Urologic Oncology
Memorial Sloan-Kettering Cancer Center – New York, NY
Yu Chen, MD, PhD, Memorial Sloan-Kettering Cancer Center
Michael J. Morris, MD, Memorial Sloan-Kettering Cancer Center
Dana E. Rathkopf, MD, Memorial Sloan-Kettering Cancer Center
Professor John Fitzpatrick, Irish Cancer Society, Dublin, Ireland
Full faculty disclosure will be provided at the activity.
CME Provider and Supporter(s): This event is sponsored by the Society for Translational Oncology (STO) and the activity is supported by educational grants from Bayer Healthcare Pharmacueticals and Algeta US, Janssen Biotech, Inc., administered by Janssen Services, LLC, and Sanofi Oncology.
Any additional funding confirmed will be acknowledged at the live event.
Brought to you in partnership with
When & Where
Society for Translational Oncology
The mission of the Society for Translational Oncology (STO) is to speed the discovery and translation of important new treatments to global oncology practice.
STO is tax-exempt as a 501(c)(3) foundation (EIN: 20-3186261).